Advertisement
ACT

MAR. 1/2016

Advertisment

news roundup

PCORI Pushes for Patient Access to EHRs

The initiative encourages patients to share their health information with researchers to support studies that have been identified as highly relevant.


CISCRP Collaborates with Euro Groups on Patient Education

CISCRP's first international meeting, AWARE for All, will be held in London on March 7.

iCardiac Launches Wide-Scope Safety Study

The late phase respiratory and cardiac safety study will be conducted at sites in 28 countries and include about 340,000 pulmonary function tests and 90,000 ECG reviews.

Academic Investigators Not Reporting Trial Results

29% of completed clinical trials led by investigators at major U.S. academic centers were published within two years of completion.

In this edition

CISCRP Collaborates with Euro Groups on Patient Education
Orphan Drugs Remain Orphans if They Don’t Reach Patients
PCORI Pushes for Patient Access to EHRs
Oncology— Advocates Press for More Coordinated Oversight of Cancer Treatments

Subscribe

Subscribe

Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »


Events


Advertisment

Oncology

Advocates Press for More Coordinated FDA Oversight of Cancer Treatments

The approach aims to address the regulatory confusion that has resulted from the emergence of more combination cancer treatments that now are regulated by different FDA Centers.


Immunotherapy. It’s Working.

The immune system is an ideal anti-cancer agent because it controls an array of diverse immune cells that have a high degree of specificity and the ability to distinguish minute chemical alterations.


Meeting the Challenges of Orphan Drug Development

In order to enhance the clinical trial process for participants, as well as improve study outcomes, sponsors frequently utilize the experiences and knowledge of patients and caregivers in the process of trial design.

Articles

Long-Term Electrocardiographic Monitoring: Time to Rethink What We Know?

Technology has advanced even further and recordings can be taken over weeks or months. It is, once again, time to rethink “what we know.”


Blog Posts

Orphan Drugs Remain Orphans if They Don’t Reach Patients

The main issue is patient access to treatments, with an estimated one-third of all rare disease patients not receiving the medicines that are already approved for their condition.


Marketplace

DIA 2016 brings together global thought leaders and innovators - from industry, academia, regulatory and government agencies, health, patient, and philanthropic organizations - conversing about the future of therapeutics, and how they affect you. Click here to watch a brief video and visit here for more information.

Get the full picture

Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription

Watch ACT TV for interviews with
Clinical Trials Experts


Ask the editor

Lisa Henderson
Editor in Chief
[email protected]

Advertise

Mike Tessalone
Publisher
[email protected]